AKT1 and anemia: Furthermore, monomethyl auristatin inactivates the Akt/mTOR pathway [17] and a classical side effect of mTOR inhibitors like rapamycin and temsirolimus is anemia due to eryptosis with erythrocyte shrinkage, membrane scrambling and release of phospholipids [18].